Tight control and treat-to-target in axial spondyloarthritis. Where are we?

Wendling, Daniel; Claudepierre, Pascal; Goupille, Philippe; Pham, Thao; Prati, Clément

doi:10.1016/j.jbspin.2021.105263

Cited by 8 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In summary, IV golimumab provided clinically meaningful improvements in signs and symptoms of AS through 1 year regardless of duration of IBP symptoms; furthermore, greater proportions of patients with early versus late disease were able to achieve inactive disease. These data support timely treatment for optimal outcomes for patients with AS, in keeping with the emergence of a treat-to-target strategy for AS 38,39 . This post hoc analysis also shows that BASDAI 50 and ASDAS inactive disease responses were discriminating outcomes for patients with early versus late disease.…”

Section: Discussionsupporting

confidence: 71%

“…These data support timely treatment for optimal outcomes for patients with AS, in keeping with the emergence of a treat-to-target strategy for AS. 38 , 39 This post hoc analysis also shows that BASDAI 50 and ASDAS inactive disease responses were discriminating outcomes for patients with early versus late disease. Further research is needed to determine the long-term benefits of initiating treatment to patients earlier in the disease process.…”

Section: Discussionmentioning

confidence: 57%

See 1 more Smart Citation

Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study

et al. 2022

View full text Add to dashboard Cite

Background/Objective: This post hoc analysis assessed efficacy and safety of intravenous (IV) golimumab in ankylosing spondylitis (AS) patients with early disease (ED) versus late disease (LD). Methods:The phase 3, double-blind, GO-ALIVE study randomized patients to IV golimumab 2 mg/kg at weeks 0 and 4 and then every 8 weeks through week 52, or placebo at weeks 0, 4, and 12 with crossover to IV golimumab at week 16. Clinical efficacy was assessed by ≥20% improvement in Assessment of Spondyloarthritis International Society response criteria (ASAS20), ≥50% improvement in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI 50), and Ankylosing Spondylitis Disease Activity Score (ASDAS) <1.3 (inactive disease). Using self-reported duration of inflammatory back pain (IBP), patients were grouped into quartiles: first = ED and fourth = LD. Descriptive statistics summarized efficacy and safety findings through 1 year.Results: Early disease patients (n = 60) were ~10 years younger and had shorter median AS (IBP) symptom duration (2-3 years) versus LD patients (n = 52; 21-24 years). At week 16, numerically higher proportions of golimumab-than placebo-treated patients achieved ASAS20 (ED: 71% vs. 32%; LD: 67% vs. 21%), BASDAI 50 (ED: 40% vs. 12%; LD: 33% vs. 7%), and ASDAS <1.3 (ED: 17% vs. 4%; LD 8% vs. 0%) regardless of IBP duration. Efficacy was durable through 1 year of treatment; however, response rates were numerically higher in patients with ED versus LD. Through week 60, adverse events and serious adverse events, respectively, were reported by 46% and 3% of ED patients and 61% and 2% of LD patients. Conclusion: Prompt diagnosis of AS and early treatment with IVgolimumab may yield more robust improvements in disease activity.

show abstract